Immune-modulating and anti-vascular activities of two xanthenone acetic acid analogues: A comparative study to DMXAA

International Journal of Oncology

Volumn 34, Issue 1, 2009, Pages 273-279

  Barbera, Mariagnese ^a,b,c,e   Kettunen, Mikko I ^b,c   Caputo, Anna ^a   Hu, De En ^b,c   Gobbi, Silvia ^d   Brindle, Kevin M ^b,c   Carrara, Maria ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e HUTCHISON MRC RESEARCH CENTRE   (United Kingdom)

Author keywords

Anti vascular; Apoptosis; DCE MRI; DMXAA; NF B; TNF

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; AP 1649; AP 1897; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOFLAXONE; UNCLASSIFIED DRUG; XANTHONE 4 ACETIC ACID; 5,6 DIMETHYLXANTHENONEACETIC ACID; 5,6-DIMETHYLXANTHENONEACETIC ACID; ANTINEOPLASTIC AGENT; I KAPPA B KINASE; TUMOR NECROSIS FACTOR ALPHA; XANTHONE DERIVATIVE;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL LINE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG STRUCTURE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; MONOCYTE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TUMOR VASCULARIZATION; ADENOCARCINOMA; ANIMAL; CBA MOUSE; CELL CULTURE; CELL PROLIFERATION; CELLULAR IMMUNITY; CYTOLOGY; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; IMMUNOLOGY; LEUKEMIA; METABOLISM; MICROCIRCULATION; OVARY TUMOR; PATHOLOGY; PHOSPHORYLATION; SARCOMA; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; FEMALE; FLOW CYTOMETRY; HUMANS; I-KAPPA B KINASE; IMMUNITY, CELLULAR; LEUKEMIA; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED CBA; MICROCIRCULATION; NF-KAPPA B; OVARIAN NEOPLASMS; PHOSPHORYLATION; SARCOMA, EXPERIMENTAL; TUMOR NECROSIS FACTOR-ALPHA; UMBILICAL VEINS; XANTHONES;

EID: 60749129332     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000149     Document Type: Article

References (31)

1. Griggs J, Metcalfe JC and Hesketh R: Targeting tumour vasculature: the development of combretastatin A4. Lancet Oncol 2: 82-87, 2001.
2. Denekamp J, Hill SA and Hobson B: Vascular occlusion and tumour cell death. Eur J Cancer Clin Oncol 19: 271-275, 1983.
3. Arap W, Pasqualini R and Ruoslahti E: Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279: 377-380, 1998.
4. Ran S and Thorpe PE: Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy. Int J Radiat Oncol Biol Phys 54: 1479-1484, 2002.
5. Carpenito C, Davis PD, Dougherty ST and Dougherty GJ: Exploiting the differential production of angiogenic factors within the tumor microenvironment in the design of a novel vascular-targeted gene therapy-based approach to the treatment of cancer. Int J Radiat Oncol Biol Phys 54: 1473-1478, 2002.
6. Baguley BC and Ching LM: DMXAA: an antivascular agent with multiple host responses. Int J Radiat Oncol Biol Phys 54: 1503-1511, 2002.
7. Baguley BC and Ching L-M: Immunomodulatory action of xanthenone anticancer agents. Biodrugs 8: 119-127, 1997.
8. Pedley RB, Boden JA, Boden R, Boxer GM, Flynn AA, Keep PA and Begent RH: Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents. Cancer Res 56: 3293-3300, 1996.
9. Zwi LJ, Baguley BC, Gavin JB and Wilson WR: Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol Res 6: 79-85, 1994.
10. Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ and Wilson WR: Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 78: 439-445, 1998.
11. Thomsen LL, Ching LM, Zhuang L, Gavin JB and Baguley BC: Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. Cancer Res 51: 77-81, 1991.
12. Philpott M, Ching LM and Baguley BC: The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor. Eur J Cancer 37: 1930-1937, 2001.
13. Valenti P, Fabbri G, Rampa A, Bisi A, Gobbi S, Da Re P, Carrara M, Sgevano A and Cima L: Synthesis and antitumor activity of some analogues of flavone acetic acid. Anticancer Drug Des 11: 243-252, 1996.
14. Valenti P, Bisi A, Rampa A, Gobbi S, Belluti F, Da Re P, Cima L and Carrara M: Synthesis of flavone-2′-carboxylic acid analogues as potential antitumor agents. Anticancer Drug Des 13: 881-892, 1998.
15. Valenti P, Bisi A, Rampa A, Belluti F, Gobbi S, Zampiron A and Carrara M: Synthesis and biological activity of some rigid analogues of flavone-8-acetic acid. Bioorg Med Chem 8: 239-246, 2000.
16. Gobbi S, Rampa A, Bisi A, Belluti F, Valenti P, Caputo A, Zampiron A and Carrara M: Synthesis and antitumor activity of new derivatives of xanthen-9-one-4-acetic acid. J Med Chem 45: 4931-4939, 2002.
17. Gobbi S, Rampa A, Bisi A, Belluti F, Piazzi L, Valenti P, Caputo A, Zampiron A and Carrara M: Synthesis and biological evaluation of 3-alkoxy analogues of flavone-8-acetic acid. J Med Chem 46: 3662-3669, 2003.
18. Gobbi S, Belluti F, Bisi A, Piazzi L, Rampa A, Zampiron A, Barbera M, Caputo A and Carrara M: New derivatives of xanthenone-4-acetic acid: synthesis, pharmacological profile and effect on TNF-alpha and NO production by human immune cells. Bioorg Med Chem 14: 4101-4109, 2006.
19. Carrara M, Zampiron A, Barbera M, Caputo A, Bisi A, Gobbi S, Belluti F, Piazzi L, Rampa A and Valenti P: Mono- or difluorinated analogues of flavone-8-acetic acid: synthesis and in vitro biological activity. Anticancer Res 25: 1179-1185, 2005.
20. Evelhoch JL: Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 10: 254-259, 1999.
21. Pilat MJ and Lorusso PM: Vascular disrupting agents. J Cell Biochem 99: 1021-1039, 2006.
22. Lippert JW III: Vascular disrupting agents. Bioorg Med Chem 15: 605-615, 2007.
23. De Forni M, Chabot GG, Armand JP, Gouyette A, Klink-Alak M and Recondo G: Phase I and pharmacology study of flavone acetic acid administered two or three times weekly without alkalinization. Cancer Chemother Pharmacol 35: 219-224, 1995.
24. Atwell GJ, Rewcastle GW, Baguley BC and Denny WA: Synthesis and anti-tumour activity of topologically-related analogues of flavoneacetic acid. Anticancer Drug Des 4: 161-169, 1989.
25. Rewcastle GW, Atwell GJ, Baguley BC, Boyd M, Thomsen LL, Zhuang L and Denny WA: Potential antitumor agents. 63. Structure-activity relationships for side-chain analogues of the colon 38 active agent 9-oxo-9H-xanthene-4-acetic acid. J Med Chem 34: 2864-2870, 1991.
26. Rewcastle GW, Atwell GJ, Palmer BD, Boyd PD, Baguley BC and Denny WA: Potential antitumor agents. 62. Structureactivity relationships for tricyclic compounds related to the colon tumor active drug 9-oxo-9H-xanthene-4-acetic acid. J Med Chem 34: 491-496, 1991.
27. Rewcastle GW, Atwell GJ, Li ZA, Baguley BC and Denny WA: Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9Hxanthene-4-acetic acids. J Med Chem 34: 217-222, 1991.
28. McKeage M and investigators A-Sg: Phase Ib/II study of DMXAA combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC). J Clin Oncol 24: 7102, 2006.
29. Wang LC, Reddy CB, Baguley BC, Kestell P, Sutherland R and Ching LM: Induction of tumour necrosis factor and interferon-gamma in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites. Biochem Pharmacol 67: 937-945, 2004.
30. Engelmann H, Holtmann H, Brakebusch C, Avni YS, Sarov I, Nophar Y, Hadas E, Leitner O and Wallach D: Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol Chem 265: 14497-14504, 1990.
31. Zhao L, Ching LM, Kestell P and Baguley BC: The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br J Cancer 87: 465-470, 2002.